News - Merck & Co, Global

Filter

Current filters:

Merck & CoGlobal

Popular Filters

Modest growth forecast for global migraine market to 2023

Modest growth forecast for global migraine market to 2023

13-03-2014

The global migraine treatment market value is expected to undergo a modest increase over the coming years,…

CoLucid PharmaceuticalsGloballamiditanMarkets & MarketingMerck & CoMK-1602NeurologicalNuPathePharmaceuticalTeva Pharmaceutical IndustriesZecuity

Global asthma market to reach 159 million lifetime cases by 2022

16-06-2013

Over 300 million people suffer from asthma, which translates to a drug market worth over $15 billion.…

GlaxoSmithKlineGlobalMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySeretideSingulair

Merck & Co in-licenses Chimerix antiviral; Fiocruz to make ARVs in Africa

24-07-2012

USA-based Chimerix, a venture-funded biotech focused on developing novel oral antivirals, has announced…

Anti-viralsChimerixCMX001CMX157FiocruzGlobalLicensingMarkets & MarketingMerck & CoPharmaceuticalRest of the World

Cancer vaccines market set to see change, will grow to over $9 billion by 2018

24-10-2011

The global cancer vaccines market in seven key markets (the USA, France, Germany, Italy, Spain, UK and…

CervarixDendreonGardasilGlaxoSmithKlineGlobalMarkets & MarketingMerck & CoOncologyPharmaceuticalProvengeVaccines

Back to top